Antisense oligonucleotides have been shown to beunique drugs that achieve their effect by targetingmRNA with which they can hybridize and specificallyblock gene expression, offering the possibility ofspecific, rational drug design. However, there havebeen many concerns that have limited enthusiasm forthe development of these drugs from the preclinical to